Drugs / BioTTT001
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06283134 | Mar 2026 → Dec 2027 expected | colorectal cancer | China Medical University, China | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07150767 | Mar 2025 → Mar 2027 | breast cancer | Beijing Bio-Targeting Therapeutics Technology Co., Ltd | Withdrawn | No outcome recorded |
| Phase 1 | NCT06215846 | May 2024 → May 2026 overdue | cancer | Beijing Bio-Targeting Therapeutics Technology Co., Ltd | Enrolling by invitation | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07264569 | Jun 2025 → Dec 2027 expected | malignant tumor of meninges | Henan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06763965 | Nov 2024 → Jul 2027 expected | malignant glioma | Beijing Bio-Targeting Therapeutics Technology Co., Ltd | Enrolling by invitation | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06283121 | Apr 2024 → Nov 2027 expected | gastric cancer | China Medical University, China | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BioTTT001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07150767 ↗ |
| Route | Other | “BioTTT001 intraperitoneal perfusion” NCT06283121 ↗ |